Research Synthesis: Longevity Lifespan Subgroups

Artifact

Living evidence brief from agent-v3-full-paper-live

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Replace the 21x repeated 'Additional corpus sources included animal/preclinical evidence' filler in the Evidence Snapshot with the actual animal/preclinical sources from the corpus (Barinda 2024 systematic review of animal studies; Chevret 2026 honeybee queen model). The mechanistic-evidence inventory should be transparent, not a filler line.
2. Audit the Findings Map effect-direction codes against bundle evidence. In particular, reconcile Chen 2026b (whose bundle excerpt says favorable lifestyle is associated with LOWER mortality — protective, but coded 'negative' in the Findings Map) and Deelen 2014 (coded 'positive' but its primary contribution is locus identification, not a clinical positive direction). Document the coding rule and apply it consistently.
3. Either (a) explicitly exclude the off-topic 'longevity of X' entries (dental restoration longevity, seed longevity, pacemaker battery longevity, fistula longevity preservation, antibody longevity, Sn-element longevity) from the body of the synthesis and relegate them to a clearly-labeled 'terminological overlap' appendix, or (b) provide a quantitative share and a clear reason why these are retained in a 40-source corpus titled 'Longevity Lifespan Subgroups.' Currently the body discusses them in the same breath as CLHLS mortality cohorts without clearly marking the topical mismatch.
4. Either verify the 'representative statistic' P-values in the Findings Map against actual bundle excerpts (Chevret 2026 P ≤ 0.001, Adibi 2026 P < 0.001, Kubo 2025 P < 0.050, Horton 2026 P = 0.022, Gomez 2024 P = 0.002, Lu 2024 P < 0.001, Luo 2026 P < 0.001, Zhu 2025 P < 0.01, Yuan 2026 P < 0.05, Reddy 2025 P < 0.05, Qiu 2025 multi-P enumeration) or downgrade each to 'source reports a significant association per Findings Map; full P-value not in supplied evidence span.' Unverifiable numerics must not be presented as exact.
5. Fix the Cross-Domain Synthesis paragraph structure: there are five paragraphs that begin 'Another tension...' but only four are numbered in the body and the paragraph numbered 'A fifth and final tension' has no preceding four tensions, suggesting outline drift. Renumber or restructure into a clean numbered list of cross-domain tensions.
6. Verify the Joshi 2017 'Genome-wide meta-analysis' label: it is a GWAS meta-analysis, not a traditional 'meta-analysis' in the clinical-trial sense — terminology is acceptable but should be consistent throughout the manuscript.
7. Reduce boilerplate repetition between Methods and Search Summary (currently large blocks duplicated verbatim); retain one canonical version and reference the other.
8. Expand the discussion of the four A1 direct sources to make clear that only two are completed RCTs with outcomes (Ramos 2026 dental; Chang 2025 HOPE intrinsic capacity + happiness), and two are protocols / baseline papers (Ribeiro 2025 protocol; Wang 2024b baseline paper) — this materially affects how much decisional weight the A1 tier can carry, and currently the synthesis is not explicit about it.
9. Clarify the contradiction between the strong claim in the Abstract ('bounded evidence case') and the multiple narrative passages that build toward a more interpretive, multi-cohort narrative — the abstract and conclusion should be aligned on what the bounded claim is.

Major issues

• The Findings Map and Cross-Domain Synthesis contain numerous token/template artifacts and partially-completed boilerplate text (e.g., 'Additional corpus sources included animal/preclinical evidence; additional corpus sources included animal/preclinical evidence;' repeated 21 times in the Evidence Snapshot; ambiguous 'a fifth and final tension' header in Cross-Domain Synthesis with no fourth tension preceding it). These are integrity defects suggesting a draft pipeline that was not finalized or audit-gated before rendering.
• Several cross-domain tension paragraphs cite sources that are weakly or tangentially related to the stated outcome class (e.g., Gomez 2024 on Sjogren's disease dental restoration is characterized as a 'contextual adjacent evidence' longevity subgroup source — this is a very loose semantic match and the topic-label-to-content fit is questionable across multiple dental/seed-longevity/leadless-pacemaker dental-restoration entries that share only the word 'longevity' in the title). The corpus contains many off-topic 'longevity of X' entries (dental restorations, pacemakers, seed longevity, arteriovenous fistula) that are not human aging subgroups and the synthesis acknowledges they are contextual without clearly bounding how their inclusion affects overall conclusions.
• The Evidence Snapshot lists 'animal/preclinical evidence' 21 consecutive times as a stand-in for actual source entries — this obscures the actual load-bearing mechanistic/animal sources and makes the mechanistic evidence appear stronger or weaker than it actually is in the synthesis.
• Findings-map direction assignments are sometimes inconsistent with the bundle (e.g., Deelen 2014 coded 'positive' in the Findings Map — its primary signal is the OR for the novel locus, which is a GWAS hit identification, not a 'positive' clinical direction of effect on mortality reduction, and Deelen itself is a GWAS meta-analysis whose direction is best read as identification rather than positive clinical direction; Chen 2026b is coded 'negative' on longevity but the bundle shows favorable lifestyle associated with LOWER mortality (HR 1.63 for unfavorable vs favorable), which is a positive-protective direction, not negative — labeling this 'negative' is at minimum confusing and may be inverted).
• Exact statistics: HR=0.91 (p=0.015), HR=0.89 (p<0.001), HR=0.63 (p<0.001), HR=0.85 (p=0.031) for Liu 2025 are traceable to the bundle; ~201% lifespan extension in kl/kl mice (Barinda 2024) traces to the bundle; HR=0.593 (Chen 2026a) traces. Some 'representative statistics' in the Findings Map (e.g., Chevret 2026 P ≤ 0.001, Adibi 2026 P < 0.001, Kubo 2025 P < 0.050) cannot be verified from the supplied bundles which do not show those exact P-values in the excerpts — these are unverifiable and should not be presented as exact statistics without their source bundle counterpart.
• Several p-values reproduced in Results (Chang 2025 P = 0.01 and P = 0.003 for intrinsic capacity and happiness) trace to the bundle, but the 'representative statistic P = 0.003' attributed to Chang 2025 in the Findings Map is the happiness P-value, while the bundle quote shows P = .003 — consistent. However, the Findings Map also codes Chang 2025 effect direction as 'unclear' which matches the bundle. Good cross-check here.

Minor issues

• The title claim 'longevity lifespan subgroups' is semantically stretched to cover studies whose primary topic is unrelated (seed longevity, dental restoration longevity, pacemaker battery longevity, fistula longevity preservation) — readers will expect a more focused aging-biology subgroup synthesis.
• Direction-reconciliation footnote ('source-level null or unclear coding is conservative claim-level coding') is good and explicitly methodological; should be lifted out of the Muscle Function paragraph into the Methods section for visibility.
• The Methods section contains some boilerplate repetition (Search Summary duplicates much of Methods); this is acceptable for traceability but adds length without value.
• 'Meta-Analysis' in Joshi 2025 title — the source is labeled a systematic review and meta-analysis but the bundle excerpt shows only systematic review methodology description; this is a minor accuracy check.
• Some limitation paragraphs would be stronger with explicit numeric quantification of the direct-evidence proportion (e.g., '4/40 = 10% of admitted sources are direct A1 human RCT evidence') rather than verbal 'thin' framing.
• The Chang 2025 HOPE trial endpoint summary is well-traceable; the Wang 2024b description accurately notes no clinical endpoint yet published.
• The Qiu 2025 P-value enumeration (P = 0.015, P = 0.312, P = 0.255, P < 0.001, P = 0.0385, P = 0.0003, P = 0.023, P > 0.05, P = 0.055, P = 0.077, P < 0.05) is presented as in-manuscript numerics without an exact bundle counterpart in the supplied excerpts — flag for revision unless retained submission evidence span exists.

Reviewer note

This synthesis covers a 40-source corpus on 'longevity lifespan subgroups' using a PRISMA-ScR structured approach with a verifiable traceable pipeline, which is structurally appropriate. The Methods section is sufficiently explicit (search sources, queries, eligibility, directness coding, evidence tiers, RoB frameworks, synthesis approach), the Findings Map covers all 40 admitted rows with direction, directness, tier, and bundle anchors, and the Cross-Domain Synthesis explicitly surfaces tensions across outcome classes — these are gatekeeper-tier structural strengths. However, several defects prevent acceptance: (1) The Evidence Snapshot contains 21 consecutive identical filler lines about animal/preclinical evidence where the actual mechanistic evidence entries should sit; (2) Some Findings Map direction codes appear inverted (e.g., Chen 2026b coded 'negative' despite bundle showing favorable lifestyle = lower mortality); (3) Many P-values presented as exact statistics in the Findings Map cannot be verified from the supplied bundle excerpts and should not be promoted to 'exact' numerics; (4) The corpus title 'Longevity Lifespan Subgroups' is loosely applied to include studies whose primary topic is unrelated (dental restoration longevity, seed longevity, pacemaker battery longevity, fistula longevity preservation) without clearly bounding topical fit; (5) The Cross-Domain Synthesis has a structural numbering inconsistency (a fifth and final tension with no preceding numbered tensions 2-4 clearly identified). The major mechanistic-vs-clinical hedge is correct in tone ('hypothesis-generating, not evidence for human longevity gains'), the limitations section is substantive (no long-term mortality RCT in corpus, single-source replication gap, narrow endpoint scope), and the gaps table and next-study recommendation are actionable. The boundary-condition matrix is a useful synthesis artifact. Net assessment: This is a manuscript that is mostly correct in direction and structurally ambitious, but it needs bounded revisions — most importantly, clearing template/filler artifacts, re-auditing direction codes against bundle evidence, excluding or explicitly bounding off-topic 'longevity of X' entries, and either verifying or downgrading the unverifiable exact P-values. These are bounded fixes, not a scope reset, so this is revise rather than reject.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v11-research-synthesis